Table 3.
Response assessment of trabectedin plus pegylated liposomal doxorubicin total population and by number of cycles of treatment, platinum sensitivity and BRCA status
| Best response to trabectedin (unconfirmed) | Number of cycles (n = 218), n (%) | Platinum sensitivity (n = 216), n (%) | BRCA status (n = 217), n (%) | Total (n = 218), n (%) | ||||
|---|---|---|---|---|---|---|---|---|
| Fewer than six cycles (n = 83) | Six or more cycles (n = 135) | Fully sensitive (n = 89) | Partially sensitive (n = 127) | Positive (n = 34) | Negative (n = 100) | Not tested (n = 83) | ||
| CR | 3 (3.6) | 21 (15.6) | 12 (13.5) | 12 (9.4) | 5 (14.7) | 11 (11.0) | 8 (9.6) | 24 (11.0) |
| PR | 15 (18.1) | 42 (31.1) | 28 (31.5) | 28 (22.0) | 11 (32.4) | 25 (25.0) | 20 (24.1) | 57 (26.1) |
| SD | 12 (14.5) | 47 (34.8) | 21 (23.6) | 37 (29.1) | 10 (29.4) | 27 (27.0) | 22 (26.5) | 59 (27.1) |
| PD | 43 (51.8) | 19 (14.1) | 24 (27.0) | 38 (29.9) | 7 (20.6) | 29 (29.0) | 26 (31.3) | 62 (28.4) |
| Not evaluable | 0 | 3 (2.2) | 1 (1.1) | 2 (1.6) | 0 | 1 (1.0) | 2 (2.4) | 3 (1.4) |
| Not done | 10 (12.0) | 3 (2.2) | 3 (3.4) | 10 (7.9) | 1 (2.9) | 7 (7.0) | 5 (6.0) | 13 (6.0) |
| Chi‐square p value | <.001 | .40 | .94 | |||||
Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.